hotspot -WSS

hotspot

author：fashion 2025-09-27 12:22:13 - browse：658

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How one medical school became remarkably diverse
Next article： Why depression after traumatic brain injury is distinct

WSS

Bird flu surveillance in wastewater gets boost from consortium

Pushing for an NIH office for post

HHS secretary Becerra pressed on Change HealthCare cyberattack

Pushing for an NIH office for post

Investigation reveals sickle cell patients pressured into sterilizations

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

knowledge

hotspot

hotspot

Hepatitis C has a cure — but many Americans still lack access to it

John Green on his newest strategy for fighting tuberculosis

How one medical school became remarkably diverse

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

Tori Bowie and the unacceptable rates of Black maternal death

Readout Newsletter: CAR

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

Alkermes shareholders re

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

leisure time

How many hemophilia patients actually want gene therapy?

Readout Newsletter: CAR

Amid AI frenzy, a top HHS official's quest to create safeguards

As a primary care physician, here's how I hope to partner with AI

Questions and answers about ramping up H5N1 bird flu vaccine

Why depression after traumatic brain injury is distinct

hotspot

leisure time

knowledge

knowledge